Deutsche Bank sets Sarepta stock target at $136, cites risks
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Sarepta initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...
Arrowhead and Sarepta close $500 million licensing deal
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), currently trading at $20.24 and showing an 8% gain over the past week, has finalized its licensing and collaboration agreement ...
Arrowhead to receives $500M upfront in licensing pact with Sarepta
Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, ...
Business Wire1d
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ ...
Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026
The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Insider Monkey3d
Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts
In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...
Q4 EPS Estimate for Sarepta Therapeutics Raised by Analyst
Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.
Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham ...
Seeking Alpha26d
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, ...